Universal Access and Affordable Medicines | Latest Developments 2

HERA should be independent and autonomous with a clear public health mission, EPHA says

by Yannis Natsis | Feb 24, 2021 | Universal Access and Affordable Medicines | Latest Developments

EPHA’s submission to the feedback mechanism on the on the HERA (Health Emergency Preparedness and Response Authority) inception impact assessment The COVID-19 pandemic has shown that Europe has paid the price of not being prepared in the biomedical research &...

Increasing our options for cancer treatment in Europe

by European Public Health Alliance | Feb 10, 2021 | COVID-19, Non Communicable Diseases (NCDs), Universal Access and Affordable Medicines | Latest Developments

EPHA has joined a number of organisations led by EPHA member the Anticancer Fund calling for the repurposing of various drugs already widely used for non-cancer diseases which have shown promise for the treatment of cancer, allowing new cancer treatments to be...

Transparency is a fundamental pillar for the success of the EU Vaccines Strategy

by Yannis Natsis | Dec 17, 2020 | COVID-19, Universal Access and Affordable Medicines | Latest Developments

39 civil society organisations including EPHA are calling on the European Commission and EU national governments to ensure a maximum degree of transparency in the EU’s exchanges, negotiations and deals with pharmaceutical companies over COVID19 vaccines, proposing a...

Putting medicines policy under the spotlight: EPHA’s #A2MDialogues

by Yannis Natsis | Nov 14, 2020 | Universal Access and Affordable Medicines | Latest Developments

Pharmaceutical policies and access to medicines top the policy agenda especially as the COVID19 challenges bring issues such as transparency in pharma, affordability of therapeutics, role of public support in biomedical innovation to the forefront. It is now more...

Recommendations for unleashing meaningful innovation through regulatory reform

by European Public Health Alliance | Nov 10, 2020 | Universal Access and Affordable Medicines | Latest Developments, Universal Access and Affordable Medicines | Publications

What do we know when a new medicine is approved? What are the regulatory requirements for new medicines? What happens once a new drug is on the market?Following the first of the EPHA #A2MDialogues, our panelists Andrea Cipriani, Lydie Meheus, Huseyin Naci and Beate...

Transparency is needed to reap the full benefits of the EU’s investment in its Vaccines Strategy, say health NGOs

by European Public Health Alliance | Sep 18, 2020 | COVID-19, Universal Access and Affordable Medicines | Latest Developments

The COVID-19 crisis represents an unprecedented challenge for societies in the European Union as well as at a global level. The European vaccines strategy’s Advance Purchase Agreements (APAs) mechanism has been used by the EU to procure vaccines for COVID-19. We...